|
Terumo will not receive the device for evaluation; however, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.
|
|
This follow-up report is submitted to fda in accord with applicable regulations and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 13, 2024.Upon further investigation of the reported event, the following information is new and/or changed: g3 (date received by manufacturer); g6 (indication that this is a follow-up report); h2 (follow-up due to additional information); h6 (identification of evaluation codes 11, 3331, 4114, 3221, 4315).The affected sample was not returned for evaluation and photos were not provided therefore, a thorough investigation could not be performed.A representative retention sample was obtained and tested.No foaming was observed during the test performed and a root cause could not be determined.The plasma leakage is believed to be a result of prolonged usage which led to the fiber pore surfaces becoming hydrophilic through absorption of elements circulating in the blood over time.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|